New High Stocks: APO, ADBE, BRK.B, LLY, MA

Hi, tigers! Welcome to our “New High Stocks“ Column! Let’s check out the winners that continue to post strong performance and reach to new high in recent period.

1. $Apollo Global Management LLC(APO)$ rose to new high of $88.88 on 6th Sept.

Back in August, Apollo Global Management began its rally after a strong Q2 earnings report. The stock broke out of a bullish pattern, hitting a 52-week high.

This year, it has gained over 32%. Q2 revenue reached $13.7 billion, with significant growth in retirement services and net investment income.

Analysts predict continued EPS growth for the company. Full-year EPS will grow to $6.57, vs. a loss of $3.89 in 2022, then increase to $7.81 next year.

2. $Adobe(ADBE)$ rose to $569.98 on 5th Sept.

SaaS stocks have been performing well recently. As we mentioned earlier, SaaS companies are well-positioned to shape the evolution of the tech industry by integrating Generative AI into their product roadmaps.

Adobe is one of the strongest performers in AI-concepts. Adobe offered a bundled solution of its products named Adobe Creative Suite, which evolved into a subscription software as a service (SaaS) offering named Adobe Creative Cloud.

3. $Berkshire Hathaway(BRK.B)$ rose to an all-time-high of $366.47, surpassing the former high in March 2022.

Berkshire Hathaway sold $13 billion in stocks in the second quarter and bought less than $5 billion, resulting in a net sale of $8 billion in stock. This move is seen as a strategy to bolster cash reserves in preparation for a potential recession.

Buffett's cautious approach and the strong performance of $Berkshire Hathaway(BRK.B)$ may indicate a lack of confidence in the stock market, and investors are closely monitoring his next moves.

4. $Eli Lilly(LLY)$ rose to an all time high of $561.93 on 6th Sept.

Eli Lilly is making rapid progress in the field of weight loss. 

Its weight loss drugs - Tirzepatide's sales reached $1.55 billion, with second-quarter sales hitting $980 million. Lilly has also raised its annual sales projection for Tirzepatide to $4 billion.

This impressive financial report has shown investors a highly promising path in the weight loss field.

5. $MasterCard(MA)$ rose to $417.78 on 31st Aug.

Mastercard  exceeded expectations in its recent quarterly earnings report.

The company reported EPS of $2.89, beating analyst estimates by $0.05. Second-quarter revenue totaled $6.30 billion, surpassing expectations. Mastercard achieved an impressive net margin of 43.37% and a remarkable return on equity of 178.10%.

Mastercard is positioned for growth due to robust consumer spending in travel, an expanded service lineup, increased cross-border transactions, and global expansion.